RE: Research request.10 May 2022 11:03
Email sent. I would be in favour of PHE taking a 49% share in the Ireland SPV, which of course would require PHE to raise funds by way of a placing and/or debt finance. I wouldn't be concerned about "dilution" if the placing is for a profit-earning project which should enhance the value of the company.
During an interview I recall David Ryan stating that PHE would be taking a shareholding in the SPV at Protos for the FOAK, but this was a “one-off” and not the company’s general strategy, and they did not intend to take a shareholding in any of the others, at this stage anyway.
Personally, I would favour PHE taking an interest in some SPVs, but not all, depending on the company’s financial situation, for anywhere between 20% and 49%, with funding to be split between equity and debt finance. I believe that once the FOAK is up and running, it will be much easier to obtain debt finance using the SPV shareholding as collateral.
Nevertheless, PHE should continue to charge a licence fee of c£500k pa for each DMG unit, payable by the SPVs. Of course the level of the fee may be reviewed from time to time, and from project to project.